Enanta Pharma posts narrower-than-feared Q4 loss as expenses decline
WATERTOWN, Mass. - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) reported a narrower-than-expected fourth-quarter loss on Monday, as the clinical-stage biotechnology company benefited from reduced research and legal expenses. The company’s shares closed 6% higher.
Enanta posted a fourth-quarter loss of $0.87 per share, beating analyst expectations for a loss of $1.01 per share. Revenue came in at $15.13 million, slightly below the consensus estimate of $15.97 million but up from $14.6 million in the same period last year. The revenue increase was attributed to higher royalties from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET.
Research and development expenses decreased to $23.8 million from $30.8 million in the year-ago quarter, primarily due to the timing of clinical trials in the company’s RSV programs. General and administrative expenses also fell to $9.7 million from $13.7 million, reflecting lower legal expenses related to the company’s patent infringement lawsuit against Pfizer and decreased stock-based compensation.
"This past quarter marked a pivotal period for Enanta, with significant progress across our virology and immunology programs," said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. "These Phase 3-enabling results underscore zelicapavir’s ability to meaningfully reduce the duration of RSV symptoms."
The company highlighted several pipeline advancements, including the selection of EPS-3903 as its lead STAT6 inhibitor development candidate for type 2 immune-driven diseases and the nomination of EDP-978 as its KIT inhibitor clinical candidate for mast-cell driven diseases.
Enanta ended fiscal 2025 with $188.9 million in cash, cash equivalents and marketable securities. The company further strengthened its financial position in October with an upsized public offering that generated gross proceeds of $74.8 million. Management expects current resources, combined with retained royalty revenue, to fund operations into fiscal 2029.
For the full fiscal year 2025, Enanta reported revenue of $65.3 million, down from $67.6 million in fiscal 2024, and a net loss of $81.9 million, or $3.84 per share, compared to a net loss of $116.0 million, or $5.48 per share, in the previous year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
